TAYLOR, JACK, BOB, HENRY, SID, JUSTIN, CHASE, AND KALI
(Clockwise from top right)
Taylor has congenital FVII deficiency; Jack, Bob, Sid, Justin, and Chase
have congenital hemophilia with inhibitors; Kali has Glanzmann’s
thrombasthenia
Rooted in effective bleed control
1
Reaching to help more patient types than any other factor product
• 30 years of research and long-term clinical experience—more than any other rFVIIa2
– Compassionate use began enrolling in 1988
– FDA approval received in 1999
• Proven efficacy in 4 indications plus surgery—more than any other factor product1:
– Treatment of bleeding episodes and perioperative management in adults and children with:
– Hemophilia A or B with inhibitors
– Congenital FVII deficiency
– Glanzmann’s thrombasthenia with refractoriness to platelet transfusions, with or without antibodies to platelets
– Treatment of bleeding episodes and perioperative management in adults with acquired hemophilia
• More than 70 trials and registries completed, with a commitment to ongoing research3
Visit NovoSevenRT.com today to learn more.